1-6 of 6
Mark Manfredi
Close
Sort by
Journal Articles

The Investigational Aurora A Kinase Inhibitor MLN8237 in Combination with Vincristine Demonstrates Robust Anti-Tumor Activity in Preclinical B-Cell Non-Hodgkin's Lymphoma Models

Mengkun Zhang, Jessica Huck, Marc Hyer, Karuppian Kannan, Wen Chyi Shyu, Susan Chen, Mark Manfredi, Jeffrey Ecsedy
Journal: Blood
Blood (2011) 118 (21): 2733.
https://doi.org/10.1182/blood.V118.21.2733.2733
Published: 2011
Journal Articles

Treatment Emergent Mutations in NAEβ Confer Resistance to the NEDD8-Activating Enzyme Inhibitor MLN4924 in Pre-Clinical AML and DLBCL Models

Michael Milhollen, Michael Thomas, Tary Traore, Usha Narayanan, Jessica Riceberg, Todd Sells, PhD, Ben Amidon, PhD, Mark Manfredi, PhD, Neil Bence, PhD, James Brownell, PhD, Larry Dick, PhD, Erik Koenig, James Gavin, Peter G Smith, PhD
Journal: Blood
Blood (2011) 118 (21): 1413.
https://doi.org/10.1182/blood.V118.21.1413.1413
Published: 2011
Journal Articles

MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-κB–dependent lymphoma

Michael A. Milhollen, Tary Traore, Jennifer Adams-Duffy, Michael P. Thomas, Allison J. Berger, Lenny Dang, Lawrence R. Dick, James J. Garnsey, Erik Koenig, Steven P. Langston, Mark Manfredi, Usha Narayanan, Mark Rolfe, Louis M. Staudt, Teresa A. Soucy, Jie Yu, Julie Zhang, Joseph B. Bolen, Peter G. Smith
Journal: Blood
Blood (2010) 116 (9): 1515–1523.
https://doi.org/10.1182/blood-2010-03-272567
Published: 2010
Includes: Supplemental data
Journal Articles

MLN9708 Elicits Pharmacodynamic Response in the Bone Marrow Compartment and Has Strong Antitumor Activity in a Preclinical Intraosseous Model of Plasma Cell Malignancy.

Edmund Lee, Bret Bannerman, Michael Fitzgerald, Jennifer Terkelsen, Daniel Bradley, Zhi Li, Ping Li, Siegfried Janz, Brian G Van Ness, Mark Manfredi, Erik Kupperman
Journal: Blood
Blood (2009) 114 (22): 1834.
https://doi.org/10.1182/blood.V114.22.1834.1834
Published: 2009
Journal Articles

Evaluating the Antitumor Activity of MLN9708 in a Disseminated Mouse Model of Double Transgenic iMyc Ca /Bcl-X L Plasma Cell Malignancy.

Michael Fitzgerald, Yueying Cao, Bret Bannerman, Zhi Li, Olga Tayber, Ping Li, Jennifer Terkelsen, Daniel Bradley, Jonathan Frazer, Lee Silverman, PhD, Siegfried Janz, Brian G Van Ness, Erik Kupperman, Mark Manfredi, Edmund Lee
Journal: Blood
Blood (2009) 114 (22): 3835.
https://doi.org/10.1182/blood.V114.22.3835.3835
Published: 2009
Journal Articles

The Novel Proteasome Inhibitor MLN9708 Demonstrates Efficacy in a Genetically-Engineered Mouse Model of DeNovo Plasma Cell Malignancy.

Siegfried Janz, Brian G Van Ness, Vishala Neppalli, Ray Liu, Michael D Pickard, Jennifer Terkelsen, Daniel Bradley, Ling Hu, Erik Kupperman, Mark Manfredi, Edmund Lee
Journal: Blood
Blood (2009) 114 (22): 3849.
https://doi.org/10.1182/blood.V114.22.3849.3849
Published: 2009